A strong case for personalized, targeted cancer prevention

Cancer Prevention Research

Volumn 4, Issue 2, 2011, Pages 173-176

  Dawson, Marcia I ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALITRETINOIN; CELECOXIB; CYTOCHROME B; GLUTATHIONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOTRETINOIN; JANUS KINASE 2; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE; RAD54 PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR ALPHA; SELENIUM; STROMELYSIN;

ACNE CYSTICA; BLADDER CANCER; CANCER PREVENTION; CHEMOPROPHYLAXIS; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME 3P; CHROMOSOME 9P; COLORECTAL CANCER; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; GENETIC VARIABILITY; HEAD AND NECK CANCER; HUMAN; ICHTHYOSIS; LOW DRUG DOSE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SECOND CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SQUAMOUS CELL CARCINOMA; TOBACCO DEPENDENCE; TUMOR SUPPRESSOR GENE; WART VIRUS; XERODERMA PIGMENTOSUM;

HEAD AND NECK NEOPLASMS; HUMANS; INDIVIDUALIZED MEDICINE; ISOTRETINOIN; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; POLYMORPHISM, SINGLE NUCLEOTIDE; RETINOID X RECEPTOR ALPHA; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79551712489     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0386     Document Type: Review

References (32)

1. Khuri FR, Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 2006;98:441-50.
2. Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner SE, Goodman GE, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 2001;93:605-18.
3. Lee JJ, Feng L, Reshef DS, Sabichi AL, Williams B, Rinsurongkawong W, et al. Mortality in the randomized, controlled lung intergroup trial of isotretinoin. Cancer Prev Res 2010;3:738-44.
4. Lee JJ, Wu X, Hildebrandt MAT, Yang H, Khuri FR, Kim E, et al. Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res 2011;4:185.
5. Levin AA, Sturzenbecker LJ, Kazmer S, et al. 9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXR alpha. Nature 1992;355:359-61.
6. Heyman RA, Mangelsdorf DJ, Dyck JA, Stein RB, Eichele G, Evans RM, Thaller C. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 1992;68:397-406.
7. Shih TW, Lin TH, Shealy YF, Hill DL. Nonenzymatic isomerization of 9-cis-retinoic acid catalyzed by sulfhydryl compounds. Drug Metab Dispos 1997;25:27-32. (Pubitemid 27045130)
8. Drugs.com. Vesanoid, 2000-2010, posted to the Drug Information Online web site. 2009. Available from: http://www.drugs.com/pro/vesanoid.html.
9. Greene JP. An adolescent with abdominal pain taking isotretinoin for severe acne. South Med J 2006;99:992-4. (Pubitemid 44408846)
10. Papadimitrakopoulou VA, Lee JJ, William WN Jr., Martin JW, Thomas M, Kim ES, et al. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol 2009;27:599-604.
11. Santaella RM, Fraunfelder FW. Ocular adverse effects associated with systemic medications: recognition and management. Drugs 2007;67:75-93. (Pubitemid 46115915)
12. MedlinePlus. Head and neck cancer. NIH, National Cancer Institute (Bethesda, MD) ;2010.
13. Lowy DR, Munger K. Prognostic implicatons of HPV in oropharyngeal cancer. N Engl J Med 2010;363:24-35.
14. ACS. Cancer facts and figures 2010. American Cancer Society (Philadelphia, PA) ;2010.
15. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008;359:1143-54.
16. Khuri FR, Kim ES, Lee JJ, Winn RJ, Benner SE, Lippman SM, et al. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2001;10:823-9. (Pubitemid 32738594)
17. Mayne ST, Gruber SB. Emerging molecular technologies for identifying the risk of second cancers. Cancer Prev Res 2009;2:605-7.
18. Wu X, Spitz MR, Lee JJ, Lippman SM, Ye Y, Yang H, Khuri FR, Kim E, Gu J, Lotan R, Hong WK. Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large- scale evaluation of genetic variants. Cancer Prev Res 2009;2:617-24.
19. Allegra E, Garozzo A, Lombardo N, De Clemente M, Carey TE. Mutations and polymorphisms in mitochondrial DNA in head and neck cancer cell lines. Acta Otorhinolaryngol Ital 2006;26:185-90.
20. Gutierrez GJ, Tsuji T, Cross JV, Davis RJ, Templeton DJ, Jiang W, et al. JNK-mediated phosphorylation of Cdc25C regulates cell cycle entry and G(2)/M DNA damage checkpoint. J Biol Chem 2010;285:14217-28.
21. Dasgupta S, Hoque MO, Upadhyay S, Sidransky D. Mitochondrial cytochrome B gene mutation promotes tumor growth in bladder cancer. Cancer Res 2008;68:700-6. (Pubitemid 351206745)
22. Minard CG, Spitz MR, Wu X, Hong WK, Etzel CJ. Evaluation of glutathione S-transferase polymorphisms and mutagen sensitivity as risk factors for the development of second primary tumors in patients previously diagnosed with early-stage head and neck cancer. Cancer 2006;106:2636-44.
23. Wang J, Lippman SM, Lee JJ, Yang H, Khuri FR, Kim E, et al. Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurence in head and neck squamous cell carcinoma. Carcinogenesis 2010;31:1755-61.
24. Zhang X, Yang H, Lee JJ, Kim E, Lippman SM, Khuri FR, et al. MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. Carcinogenesis 2010;31:2118-23.
25. Decensi A, Serrano D, Bonanni B, Cazzaniga M, Guerrieri-Gonzaga A. Breast cancer prevention trials using retinoids. J Mammary Gland Biol Neoplasia 2003;8:19-30. (Pubitemid 38129948)
26. Chan AT, Zauber AG, Hsu M, Breazna A, Hunter DJ, Rosenstein RB, et al. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology 2009;136:2127-36.
27. LipkinSM, Chao EC, Moreno V, Rozek LS, Rennert H, Pinchev M, et al. Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev Res 2010;3:597-603.
28. Penney KL, Schumacher FR, Li H, Kraft P, Morris JS, Kurth T, et al. A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prev Res 2010;3: 604-10.
29. Chen M, Hildebrandt MAT, Clague J, Kamat AM, Picornell A, Chang J, et al. Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer. Cancer Prev Res 2010;3:1235-45.
30. Patterson F, Schnoll RA, Wileyto EP, Pinto A, Epstein LH, Shields PG, et al. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther 2008;84:320-5.
31. Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, Lin J, et al. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 2009;27:857-71.
32. Settle K, Posner MR, Schumaker LM, Tan M, Suntharalingam M, Goloubeva O, et al. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res 2009;2:776-81.